-
[News] First-line treatment of prostate cancer, Olapali Phase III PROpel test is highly positive
Time of Update: 2021-10-11
Author: John Guide: Recently, the results of the interim analysis of AstraZeneca Olapali Phase III PROpel trial have been released, showing high rates in first-line treatment of patients with metastatic castration-resistant prostate cancer The level is positive .
-
[2021EAU] Progress in precise diagnosis and precise treatment of prostate cancer
Time of Update: 2021-10-03
The above research results indicate that the frequency of gene mutations in Chinese HSPC patients is different from previous reports, and that DDR deficiency/endocrine-related gene mutations have nothing to do with the clinical outcome of neoadjuvant therapy .
-
Professor Wang Feng: The Department of Nuclear Medicine and Urology work side by side, and radioligand therapy has a bright future in prostate cancer.
Time of Update: 2021-10-02
During the "2021 Novartis Urinary Tumor Day (NUTD)-Sharing the Kidney Potential and Enjoying New Life" conference, Yimaitong was fortunate to invite Professor Wang Feng, Director of the Nuclear Medicine Department of Nanjing First Hospital, to share radioligand therapy in prostate cancer The broad application prospects .
-
Targeted therapy for patients with advanced prostate cancer with lack of PTEN
Time of Update: 2021-10-02
This article is from NEJM Journal Watch Targeting Advanced Prostate Cancer Patients with PTEN LossPTEN Loss Targeting Therapy of Advanced Prostate Cancer Patients Comment Author: Robert Dreicer, MD, MS, MACP, FASCOAKT and Androgen Receptor Pathway Inhibitors Treatment can prolong the progression-free survival of patients with PTEN deficiency .
-
Express first-line treatment of advanced bladder cancer, blockbuster PD-1 inhibitor was fully approved by the US FDA
Time of Update: 2021-10-02
▎MSD, editor of WuXi AppTec's content team, announced today that the US FDA has approved the label update of the anti-PD-1 therapy Keytruda for the first-line treatment of advanced urothelial cancer (bladder cancer) .
-
Nat Commun Mao Ninghui/Zhang Zeda propose precise treatment strategies for different subtypes of prostate cancer with PI3K pathway mutations
Time of Update: 2021-10-02
Finally, the authors performed PI3K signaling pathway inhibition tests for PTEN wild-type, PTEN mutant deletion, p110α activating mutations, and p110β activating mutations in various prostate and breast cancers, looking for different molecular subtypes in tumors with PI3K mutations.
-
European Urology (IF=21) What is the healthiest frequency of sexual activity?
Time of Update: 2021-10-02
iNature prostate cancer (PCa) accounts for approximately 15% of all newly diagnosed cancers in men worldwide, and the global burden of disease continues to increase .
The study is a prospective cohort study of participants in the follow-up study of health professionals, using self-reported data on the average monthly ejaculation frequency .
-
A 7-day short course of antibiotics for men with a fever-free urinary tract infection
Time of Update: 2021-10-02
This article is from the NEJM Journal Watch Antibiotic Treatment Duration for Afebrile Men with Urinary Tract Infections.
Comment on these results to support the use of a 7-day course of antibiotics for male patients with no fever but with UTI symptoms, and suggest that a shorter course of treatment can be studied .
-
Optimize the diagnosis and treatment strategy for mHSPC patients, greatly increase the survival rate of prostate cancer, and implement the healthy China strategy
Time of Update: 2021-10-02
▎Clinical diagnosis of low tumor burden, metastatic hormone-sensitive prostate cancer (mHSPC) (T4N1M1), acute renal failure, acute urinary retention, filling urinary incontinence, hypertension ▎ After treatment on June 10, 2021, the patient began to receive apatamide + androgen Deprivation treatment (ADT) treatment .
-
Clinical practice of shock wave lithotripsy for staghorn kidney stones
Time of Update: 2021-10-02
followed up 167 patients with staghorn stones for a long time, of which 1/3 had a follow-up period of nearly 8 years, further confirming that patients undergoing surgery progressed more slowly than patients undergoing conservative treatment, and the renal salvage rate was higher .
-
Cancer Cell Molecular typing of upper urothelial cancer and a new method for non-invasive diagnosis
Time of Update: 2021-10-02
Through RNA sequencing of 158 UTUC samples and non-difference cluster analysis, the authors identified five subtypes of expression profiles of C1-C5 .
Finally, the authors used urine sediment DNA to target and sequence 30 common mutations in UTUC, in order to evaluate the potential of molecular classification to diagnose UTUC and achieve the purpose of non-invasive inspection .
-
Preliminary exploration of new drugs: How effective are GLS inhibitors in treated renal cancer?
Time of Update: 2021-10-02
The CANTATA study explored the efficacy and safety of Telaglenastat+Cabotinib versus placebo+Cabotinib in patients with treated metastatic clear cell renal cell carcinoma (NCT03428217) .
In the placebo+cabotinib group, the median PFS of patients who received immunotherapy was 9.
-
Innovative mechanism, excellent curative effect, expect "apatamide" to be included in the national medical insurance, find the fulcrum to improve the survival rate of prostate cancer
Time of Update: 2021-10-02
Advanced prostate cancer innovative drug "Apatamide" is China's first and currently the only new androgen approved for "all types" of metastatic endocrine therapy sensitive prostate cancer (mHSPC) indications Receptor (AR) inhibitors are also China’s first new type of AR inhibitors approved for high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) indications.
-
[The Lancet] Subvert the traditional detection method and achieve a new breakthrough in the early screening of prostate cancer
Time of Update: 2021-10-02
The results of this new study are based on "Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): A prospective, population-based, randomised, open-label, non-inferiority trial" research has been published in "The Lancet Oncology", and the results show that it was developed by researchers from Karolinska Institutet Stockholm3 can be an important supplement .
-
Courier doubles the "cancer-free survival" time of patients with early bladder cancer, and the blockbuster PD-1 inhibitor is approved by the FDA
Time of Update: 2021-10-02
▎Editor of WuXi PharmaTech Content Team On August 20, 2021, Bristol Myers Squibb (BMS) announced that the US FDA has approved its PD-1 inhibitor nivolumab (nivolumab, the English product name is Opdivo) As an adjuvant therapy, patients with urothelial cancer (UC) who have undergone resection and have a high risk of recurrence, regardless of whether they have received neoadjuvant cisplatin chemotherapy, whether the lymph nodes are involved, or their PD-L1 status .
-
Molecular Cancer Li Liaoyuan’s team at Sun Yat-sen University has constructed a urine extracellular vesicle circRNA classifier to better diagnose prostate cancer
Time of Update: 2021-10-02
To this end, the study used RNA sequencing to identify candidate circRNAs from the urine extracellular vesicles of 11 high-grade prostate cancer patients and 11 case-matched benign prostatic hyperplasia patients .
-
CRN GU 16-257 Study: Immunotherapy is added to MIBC to help patients in complete clinical remission
Time of Update: 2021-10-02
The enrolled patients received 4 cycles of gemcitabine + cisplatin + nivolumab treatment, followed by clinical re-staging, including urine cytology, bladder MRI/CT, cystoscopy, and bladder/prostate urethral biopsy .
Table 1 year survival rate analysis conclusion: TURBT + gemcitabine + cisplatin + nivolumab reached the strictly defined cCR in most MIBC patients .
-
SPAQI Consensus Statement: Perioperative Management of Endocrine and Urinary System Drugs
Time of Update: 2021-10-02
Preoperative management of endocrine, hormonal, and urologic medications: Society for Perioperative Assessment and Quality Improvement (SPAQI) consensus statement.
Copyright information This article was translated, written or commissioned by the "NEJM Frontiers of Medicine" jointly created by the Jiahui Medical Research and Education Group (J-Med) and the "New England Journal of Medicine" (NEJM) .
-
MRI examination optimizes biopsy decision for men with elevated PSA
Time of Update: 2021-10-02
This article is from the NEJM Journal Watch MRI Evaluation of Men with Elevated Levels of Prostate-Specific Antigen.
For men whose prostate cancer screening shows elevated prostate-specific antigen (PSA) levels, urologists are increasingly using magnetic resonance imaging (MRI) to guide biopsy decisions; MRI can also help target suspicious areas Biopsy .
-
Because of the azithromycin tablets in the prescription, the doctors and pharmacists "fight"?
Time of Update: 2021-10-02
In 2021, The New England Journal of Medicine published a randomized, double-blind, controlled clinical trial aimed at comparing the efficacy of single-dose azithromycin and doxycycline 7-day therapy in the treatment of men with male-to-male chlamydia infection.
